The intricate interplay among IGF-1R, IGF-1, and GM-CSF highlights potential therapeutic targets for precise control of NPC bone metastasis, providing valuable insights for developing targeted interventions. The gene discussed is CSF2; the disease is nasopharyngeal carcinoma.